regorafenib
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Bayer cancer drug meets Phase III goal
April 3, 2012Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib
Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Bayer’s colorectal cancer drug increases survival
January 19, 2012Research and Development, Sales and Marketing Bayer, colectoral cancer, regorafenib
Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …
FDA fast-tracks Bayer’s GIST drug regorafenib
May 10, 2011Sales and Marketing Bayer, GIST, regorafenib
The assessment of Bayer HealthCare’s investigational drug regorafenib is to be fast-tracked by US authorities for the treatment of stomach …
Bayer’s regorafenib gains orphan status for GIST
February 4, 2011Research and Development, Sales and Marketing Bayer, FDA, GIST, gastrointestinal stromal tumours, orphan drug, regorafenib
Bayer’s investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumours (GIST) …
Bayer colon cancer drug moves into phase III
May 11, 2010Research and Development Bayer, colorectal cancer, regorafenib
Bayer Schering Pharma will shortly begin phase III tests of its investigational compound regorafenib for patients with metastatic colorectal cancer. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
